Poster Abstracts Thursday, November 10, 2005 $445

started. Female patient received 30 lakh units over 48 hours and male patient 23 lakh units over 24 hours. Results: Both the patients made complete recovery with no complica- tions or sequelae. Conclusion: Local thrombolytic therapy is worth considering in dire circumstances of cortical vein thrombosis. But large, randomized, controlled, trials are necessary before making any finn recommenda- tions, to use it as the first line mode of therapy. NB: Recording of the procedure will be displayed.

1355 Shnvastalin p~events increasing NINIP-9 activity in Acute Phase of Ischemie Stroke

Szczepanska-Szerej, A ~, Kurzepa, jl:~, XNojczal ' j1, Stelmasiak, Z l, Stryjecka-Zinmler, M ~. 1Department of Neurology, Medical University in Lublin, Polan& 2Department of Biochemistry and Molecular Biology', Medical University in Lublin, Poland

Background: Matrix metalloproteinases (MMP), especially gelatinases MMP-2 and MMP-9 are involved in remodeling extracelhilar matrix and play an important role in biochemical processes within the ischemic focus. The therapeutic benefit of M M P intffbitors is under study in several experimental model. Our purpose was to analyze whether H M G CoA reductase inhibitors (statins) involve gelatinases inhibition in acute ischemic stroke (AIS). Methods: Free of inflammatory symptoms patients with AIS were randomly divided in to two groups: Group I - non-treated of statins (in - 15), Group II treated from the first day of stroke with 40 mg of simvastatin (n -- 15). There were no sigtffficant differences in age, risk-factor profile and stroke severity between both groups. Activities of MMP-2 and MMP-9 in blood serum were serially measured using gelatin zymography on admission (within 24 h, before treat- ment) 3, 5 and 7 days from the symptoms onset. These results were compared with results of age-matched, healthy control group (in - 10). Statistics were performed using Mann-Wtfftney U and Wilcoxon's tests. Results: Activities of MMP-2 and MMP-9 on admission didn't differ from the control group. MMP-2 activity was markedly elevated on the fifth day after the stroke in Group I and Group IL MMP-9 activity was markedly increasing in Group I but not in the Group II. The results differ statistically sigtffficant (p < 0,05). MMP-9 activity in Group II remained similar as at the control group. Conclusion: The findings indicate that early treatment with simvastain for AIS can be followed by MMP-9 inhibition.

I356 First experience with a new PFO dosute device

Taaffe, M 1, Buescheck, F 1, Xaver Kleber, F 2, Windecker, S 3, Meier, B ~, Albrecht Roemer, E l, Long, K l, Lissmann-Jensen, H l, Hoffmann, I l, Middeldorf, T l, Leetz, M l, Fischer, E l, Bayard, y1, Hein, R l, Reschke, M l, Wilson, N1, Sievert, H 1. 1Cardio Vascular Center, Frankfurt Germany; 2Humbolt University Hospital, Berlin Germany; 3lnselspital, Bern, Switzerland

Background: Percutaneous PFO Closure is successfully being performed for ten years in patients with paradoxical embolism. The Velocimed Premere PFO Closure System is an occlusion device specifically desig- ned for the closure of the patent foramen ovale to prevent recurrent paradoxical embolism. It consists of two attchors made ofnitinol and is available in two sizes. A flexible braided tether holds the two anchors together allowing a variable distance between the two anchors. Methods: PFO closure with the Premere PFO Closure System has been attempted in 73 patients (mean age 47.3 years). Transesophageal echocardiography and fluoroscopy were performed two weeks and six months after the procedure. Results: The implantation of the Premere PFO Closure System was successful in 67 of the 73 patients. Five patients had large PFO

diameters and significant septal aneurysms making the attempt to implant a 15 mm device unsuccessful. The 20 mm device was not available at tiffs time. Each device was easily retrieved with the Premere delivery system without any complications. One patient had an ASD. The remaining 67 patients had no complications during the implantation or during the follow-up period. No evidence of thrombus formation on the device has been detected by echocardiography during follow-up. Conclusion: PFO closure with the Premere PFO Closure System is a feasible and safe procedure. The advantage of tiffs occluder is that it adapts very well to the anatomy of the PFO and has a low surface area leading to a low risk of thrombus formation on the left side of the heart.

1357 Hypocholeste~olemia, a novel risk facto~ of Cexvico-Cereb~al Artery Dissection

Takenobu, y1, Naritomi, H 1, Takada, T 1, Minematsu, K 1, Miyamoto, S a. 1Department of Cerebrovaseular Medicine, National Cardiovascular Center, Osaka, Japan; 2Department of Cerebrovaseular Surgery', National Cardiovascular Center, Osaka, )'apart

Baekg*ound: Cervico-cerebral artery dissection (CAD) has been increasingly recognized as an important cause of stroke, especially in young adult. While underlying arteriopathy is assumed to be a predisposing factor, the pathogenesis of CAD still remains unclear. We investigated the clinical and biochemical background factors of the CAD patients. Methods: We retrospectively evaluated consecutive CAD patients whose blood samples were collected within 24 hours of admission. The following data were collected: history of hypertension, alcohol consumption, and history of smoking. The following parameters were measured: total cholesterol (T-C), total protein, albumin, blood glucose, hemoglobin, leukocyte, and platelet count. Results: Ninety-eight CAD patients (mean age 53 years, 66 men, 79 ischemic stroke, 14 subarachnoid hemorrhage, 2 local pain, 10 asymptomatic) were enrolled in this study. 21 (121%) cases had hypocholesterolemia (T-C < 4.14 mmol/L [160 mg/dL], 5 tl' percentile of Japanese population), while 14 (14%) cases had hypercholester- olemia (T-C > 6.21 nmlol/L [240 mg/dL], 85 th percentile of Japanese population). The other factors showed no abnormal distribution. Conclusion: In CAD patients, proportion of hypocholesterolemia is greater than that of healthy population. Vascular fragility induced by hypocholesterolemia may be a cause of CAD.

1358 Rate and adequacy of cholesterol monitoring and COntrol in Dyslipidemic Stroke patients: a hospital-based study

Teng-Yeow, T ~, Tsung-Kung, L 1, Ku-Chou, C l, Jen-Wen, H a, Yu-Ching, H 1. 1First Department of Neurology, Chang Gang Memorial Hospital, Kaohsiung, Taiwan; ~Department of Physical Medicine and Rehabilitation, Chang Gang Memorial Hospital, Kaohsiung, Taiwan

Background: Lipid treatment and control is essential for stroke patients with dyslipidemia. The purpose of this study was to assess the rate and adequacy of cholesterol monitoring and control in dyslipidemic stroke patients. Method: 212 ischemic stroke patients with dyslipidemia treated with simvastatin (120 mg) per day for 6 months were recruited. The rate and adequacy of cholesterol monitoring and control were discussed. Results: The rate of cholesterol screening were 98.5% for total cholesterol (TC) , 91% for low-density lipoprotein (LDL), 97.2% for triglyceride (TG) at admission; 34.4% for TC, 31% for LDL, 33% for TG at tlffrd month and 28.7% for TC, 24% for LDL, 27.4% for TG at sixth month. The percentage of patients continue on simvastatin was 59% at third month and 48% at sixth month. Simvasatatin